Showing results (31-40 of 135) with videos related to
Sort By:
Pageof 14
Pharmacology & Therapeutics|April 14, 2023
Metabolic dependencies and targets in ovarian cancerYaqi Zhang, Yinu Wang, Guangyuan Zhao, et al.Nature|July 5, 2005
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorStephan Gasser, Sandra Orsulic, Eric J Brown, et al.Gynecologic Oncology|September 15, 2010
Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cellsBarbie Taylor-Harding, Sandra Orsulic, Beth Y Karlan, et al.Cancers|March 10, 2022
Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic TargetsRalf-Peter Czekay, Dong-Joo Cheon, Rohan Samarakoon, et al.The Journal of Clinical Investigation|March 17, 2025
High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancerHarun Ozturk, Fidan Seker-Polat, Neda Abbaszadeh, et al.Journal for Immunotherapy of Cancer|October 14, 2021
Immunological configuration of ovarian carcinoma: features and impact on disease outcomeJitka Fucikova, An Coosemans, Sandra Orsulic, et al.Oncogenesis|July 2, 2025
Lipid droplet-associated hydrolase (LDAH) knockdown enhances TAG hydrolysis and promotes ovarian cancer progression and chemoresistanceBhawna Deswal, Sameera Nallanthighal, Elahe Nikpayam, et al.Investigative Ophthalmology & Visual Science|May 10, 2014
Effects of the loss of conjunctival Muc16 on corneal epithelium and stroma in miceKumi Shirai, Yuka Okada, Dong-Joo Cheon, et al.Nano Letters|March 24, 2018
Intracellular Delivery of Nanomaterials via an Inertial Microfluidic Cell HydroporatorYanxiang Deng, Megan Kizer, Miran Rada, et al.Cells|December 23, 2022
Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease ProgressionMichael T Richardson, Maria Sol Recouvreux, Beth Y Karlan, et al.Pageof 14